

Provided by:



Thoracic Oncology Tumor Board 2024-2025

Thoracic Oncology Tumor Board 2024-2025 - 2/7/2025

February 7, 2025

8:00 AM - 9:00 AM

online

Target Audience

This program has been designed for INTERNAL MEDICINE - Hematology, INTERVENTIONAL RADIOLOGY AND DIAGNOSTIC RADIOLOGY, INTERNAL MEDICINE - Medical Oncology, PATHOLOGY - CLINICAL, INTERNAL MEDICINE - Pulmonary Disease, RADIATION ONCOLOGY, THORACIC AND CARDIAC SURGERY, PATHOLOGY - ANATOMIC, PATHOLOGY - Clinical Informatics, PATHOLOGY - Cytopathology, PATHOLOGY - Hematopathology, PATHOLOGY - Pathology-Chemical, PATHOLOGY - Pathology-Medical Microbiology, PATHOLOGY - Pathology-Molecular Genetic, INTERNAL MEDICINE - Hospice and Palliative Medicine, RADIOLOGY , SURGERY - Hospice and Palliative Medicine, RADIOLOGY - Hospice and Palliative Medicine

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Delineate institutional and national pathways/guidelines in the management of thoracic malignancy.
- 2 Discuss multidisciplinary care and discussion to improve outcomes and quality of life
- 3 Describe the critical role of radiology and pathology in the multidisciplinary management of thoracic cancer
- 4 Discuss clinical trials at the ACC and throughout the nation and to enhance enrollment in clinical trials.

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™].

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC: up to 1 MOC points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABS CC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to the ACCME for the purpose of granting ABS credit.

ABPath MOC: up to 1 MOC points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery's Continuous Certification program. It is

For more information, please contact

Megan Roy, Damaris Rodriguez

(267) 271-9735, No phone on file

megan.roy@pennmedicine.upenn.edu, Damaris.Rodriguez@Pennmedicine.upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

the CME activity provider's responsibility to submit learner completion information to the ACCME for the purpose of granting ABS credit.

Nurses: This activity is for **1.00** contact hours.

Pharmacists: This activity is not approved for pharmacy contact hours

PAs: Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

Approved for (PSRM) patient safety/risk management designation

Acknowledgement of Commercial Support*

None

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Elizabeth Gilbert, PA-C	Physician Assistant Planner	Nothing to disclose - 10/31/2024
John Kosteva, MD	Other Planning Committee Member	Nothing to disclose - 06/27/2024
Ana Kolansky, MD	Other Planning Committee Member	Nothing to disclose - 01/20/2025
Doraid Jarrar, MD	Other Planning Committee Member	Nothing to disclose - 08/25/2024
Melina Marmarelis, MD	Other Planning Committee Member	Consulting Fee-Novocure (Relationship has ended) Honoraria-Bayer (Relationship has ended) Consulting Fee-Astra Zeneca Pharmaceuticals Consulting Fee-Janssen Pharmaceuticals (J&J) Consulting Fee-Takeda Pharmaceuticals (Relationship has ended) Consulting Fee-Bristol-Myers Squibb (Relationship has ended) Grant or research support-Eli Lilly Consulting Fee-Blueprint Pharmaceuticals (Relationship has ended) Advisor-Ikena Grant or research support-Merck & Co Grant or research support-Astra Zeneca Pharmaceuticals Stocks or stock options, excluding diversified mutual funds-Gilead Sciences, Inc (Relationship has ended) Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Merck & Co Stocks or stock options, excluding

		diversified mutual funds-Portola Pharmaceuticals (Relationship has ended) Stocks or stock options, excluding diversified mutual funds-Bluebird Biosciences (Relationship has ended) Stocks or stock options, excluding diversified mutual funds-Novartis (Advanced Health Media) (Relationship has ended) Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Johnson & Johnson Advisor-Janssen Pharmaceuticals (J&J) Stocks or stock options, excluding diversified mutual funds-Pfizer, Inc. (Relationship has ended) Grant or research support-Genentech - 06/27/2024
William P Levin, MD	Other Planning Committee Member	Nothing to disclose - 07/16/2024
Michael Costello, MD	Other Planning Committee Member	Nothing to disclose - 11/12/2024
steven j Feigenberg, MD	Other Planning Committee Member	Honoraria-Astra Zeneca Pharmaceuticals (Relationship has ended) Honoraria-Varian Medical Systems (Relationship has ended) - 07/12/2024
David DiBardino, MD	Other Planning Committee Member	Consulting Fee-Olympus Consulting Fee-Johnson & Johnson Consulting Fee-Intuitive Surgical (Relationship has ended) Consulting Fee-Galvanize Therapeutics Grant or research support-Philips Grant or research support-Galvanize Therapeutics Grant or research support-Johnson & Johnson Grant or research support-ERBE - 05/01/2024
Kevin Ma, MD	Other Planning Committee Member	Grant or research support-Right Air Grant or research support-Lung Therapeutics (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Verona Pharmaceutical (Relationship has ended) Consulting Fee-Pulmonx Grant or research support-Pulmonx - 05/19/2024
Andrew Haas, MD	Other Planning Committee Member	Consulting Fee-Olympus Paid consultant-Serpex Medical Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novocure Honoraria-Imedex (Relationship has ended) Consulting Fee-Mana Therapeutics (Relationship has ended) Advisor-VisionAir - 06/28/2024
John C Kucharczuk, MD	Other Planning Committee Member	Nothing to disclose - 12/04/2024
Taine Pechet	Other Planning Committee Member	Nothing to disclose - 06/27/2024
Keith Cengel, MD, PhD	Co-Director, Faculty	Nothing to disclose - 07/12/2024
Roger B Cohen, MD	Other Planning Committee Member	Consulting Fee-Actuate Consulting Fee-Ono - 06/27/2024
Lova Sun, MD	Other Planning Committee	Honoraria-Regeneron Pharmaceuticals, Inc.

	Member	(Relationship has ended) Grant or research support-Seattle Genetics Grant or research support-Blueprint (Relationship has ended) Grant or research support-IO Biotech Grant or research support-Erasca (Relationship has ended) Grant or research support-AbbVie, Inc. Honoraria-Bayer (Relationship has ended) - 08/07/2024
Leslie Litzky, MD	Other Planning Committee Member	Nothing to disclose - 09/10/2024
Christine A Ciunci, MD	Other Planning Committee Member	Nothing to disclose - 11/29/2024
Megan Roy, MSN	Nurse Planner	Speakers Bureau-Astra Zeneca Pharmaceuticals - 11/19/2024
Aditi Singh, MD	Other Planning Committee Member	Grant or research support-Jazz Pharmaceuticals - Institutional funding (Relationship has ended) - 08/16/2024
Corey J Langer, FACP	Co-Director	Advisor-Merck & Co Grant or research support-Daiichi-Sankyo Other: DSMC member-Oncocyte Dx Other: DSMC Member-Summit Therapeutics Advisor-Regeneron Pharmaceuticals, Inc. Advisor-Astra Zeneca Pharmaceuticals Consulting Fee-Gilead Sciences, Inc Advisor-Genentech Advisor-Amgen Advisor-Mirati Grant or research support-Guardant Grant or research support-Navire (Relationship has ended) Grant or research support-Fujifilm Advisor-Novacure Membership on Advisory Committees or Review Panels, Board Membership, etc.-RTOG Foundation Advisor-Johnson & Johnson Advisor-Pfizer, Inc. Advisor-Eli Lilly - 03/29/2024

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected